University of Erlangen–Nuremberg is a public research university in the cities of Erlangen and Nuremberg in Bavaria, Germany. The name Friedrich–Alexander comes from the university's first founder Friedrich, Margrave of Brandenburg-Bayreuth, and its benefactor Alexander, Margrave of Brandenburg-Ansbach.

During the past decade, University of Erlangen-Nurenberg, Division of Hematology/Oncology conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "University of Erlangen-Nurenberg, Division of Hematology/Oncology" are "Multiple Myeloma" (2 trials). Many other conditions were trialed in "University of Erlangen-Nurenberg, Division of Hematology/Oncology" in a lesser frequency.

Most popular intervention types in "University of Erlangen-Nurenberg, Division of Hematology/Oncology" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "bortezomib" (2 trials). Other intervention names were less common.

The vast majority of trials in "University of Erlangen-Nurenberg, Division of Hematology/Oncology" are 2 trials for "All" genders.

Currently, there are NaN active trials in "University of Erlangen-Nurenberg, Division of Hematology/Oncology". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in University of Erlangen-Nurenberg, Division of Hematology/Oncology, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in University of Erlangen-Nurenberg, Division of Hematology/Oncology, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".